Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has received a drug registration certificate from the Singapore Food and Drug Administration for the drug rivaroxaban, which has been approved for market launch [1] Group 1: Product Approval - The drug rivaroxaban is primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] - It is also indicated for the treatment and prevention of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), and prevention of venous thromboembolism (VTE) in acutely ill patients [1] Group 2: Investment and R&D - As of the announcement date, the company has invested approximately RMB 3.2482 million in research and development for this drug's market launch in Southeast Asia, specifically in Thailand, Singapore, Malaysia, and the Philippines [1]

Product Development Progress - The company announced that its raw material drug, hydrochloride erlotinib, received approval for market application from the National Medical Products Administration on February 3, 2026. This drug is intended for the treatment of non-small cell lung cancer and is expected to enrich the company's product line and enhance market competitiveness [2] Performance and Operating Conditions - On January 20, 2026, the company released its annual performance forecast for 2025, estimating a net profit attributable to shareholders of between 31 million and 39 million yuan, representing a year-on-year decline of 57.40% to 66.14%. The non-recurring net profit is expected to decline by 88.76% to 92.46% year-on-year. The decline in performance is primarily attributed to intensified market competition for ibuprofen raw materials and a decrease in gross profit margin [3] Shareholder Movements - An announcement on November 12, 2025, indicated that three shareholders plan to collectively reduce their holdings in the company by no more than 2.33%. This reduction is scheduled to occur within three months following the announcement, starting 15 trading days after the disclosure. This movement may impact the company's equity structure [4] Financial Situation - Data from January 2026 shows that the company's main funds are in a net inflow state, with a net inflow of 4.9655 million yuan on January 7. This reflects short-term changes in the financial situation and resonates with market sentiment [5]

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received a "Notice of Acceptance" from the National Medical Products Administration for the marketing authorization application of injectable fosnetupitant palonosetron, which is intended for the prevention of acute and delayed nausea and vomiting induced by moderately emetogenic anticancer chemotherapy in adult patients [1] Group 1 - The drug is a compound formulation that can simultaneously activate NK-1 and 5-HT3 receptors to inhibit the vomiting reflex [1] - Currently, there are no similar injectable products approved for marketing in China [1] - The total research and development investment for this project is approximately 247 million yuan [1]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the domestic production drug registration application of melatonin granules, indicating progress in its product development in the pediatric neuropsychiatric field [1]. Group 1 - The melatonin granules are developed by Jinsai Pharmaceutical and are classified as a Category 4 chemical drug [1]. - The product aims to improve sleep difficulties associated with neurodevelopmental disorders in children by activating the MT1 and MT2 receptors in the suprachiasmatic nucleus [1]. - The indication for the product is specifically targeted at children experiencing sleep onset issues due to neurodevelopmental disorders [1].

Group 1 - The company’s subsidiary, China Resources Saike Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Bisoprolol Amlodipine Tablets from the National Medical Products Administration [1] - Bisoprolol Amlodipine Tablets are used as an alternative therapy for hypertension in patients whose blood pressure is well controlled with the same dosage of single drugs [1] - The research and development of this drug began in November 2022, with the application for market approval submitted in June 2024 and the approval expected in November 2025 [1][2] Group 2 - The global sales of Bisoprolol Amlodipine Tablets are projected to reach approximately $74.05 million in 2024, with the product "Concor AMLO?" accounting for about $44.29 million of that total [3] - In China, there are 14 approved manufacturers of Bisoprolol Amlodipine Tablets, with 13 having passed the consistency evaluation, including the company [3] - The total sales in the domestic medical and retail market for Bisoprolol Amlodipine Tablets are estimated to be around 4.29 million RMB, with Merck holding a market share of 99.90% [3]

Core Viewpoint - The announcement highlights that China Resources Double Crane Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, China Resources Saike Pharmaceutical Co., Ltd., has received a drug registration certificate for Bisoprolol Amlodipine Tablets, which is a significant development for the company's product line and market competitiveness [1][4]. Group 1: Drug Registration and Development - The drug registration certificate for Bisoprolol Amlodipine Tablets was issued by the National Medical Products Administration (NMPA) [1]. - The research and development of this drug began in November 2022, with the application for market approval submitted in June 2024 and the approval granted in November 2025 [1][2]. Group 2: Market Situation - Bisoprolol Amlodipine Tablets, developed by Merck Kft, were approved for sale in the EU in November 2017 and in China in May 2021 [3]. - The global sales of Bisoprolol Amlodipine Tablets are projected to reach approximately $74.05 million in 2024, with Merck's product "Concor AMLO?" accounting for about $44.29 million of that total [3]. - In the Chinese market, the total sales of Bisoprolol Amlodipine Tablets are estimated to be around 4.29 million RMB in 2024, with Merck holding a dominant market share of 99.90% [3]. Group 3: Impact on the Company - The approval of the drug registration certificate is expected to enhance the company's product line and market competitiveness, while also providing valuable experience for future product development [4].

Core Viewpoint - The approval of the drug registration application for Dextroamphetamine Sulfate Capsules by the National Medical Products Administration marks a significant step for the company, indicating the product is entering the review phase, which could enhance the company's product line and market competitiveness [1] Group 1 - The company's subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application of Dextroamphetamine Sulfate Capsules from the National Medical Products Administration [1] - Currently, there are no Dextroamphetamine Sulfate Capsules available in the domestic market, nor have any related products been approved for import [1] - The total R&D investment by Yichang Renfu in this project has reached approximately 90 million RMB [1]

Core Viewpoint - Huahai Pharmaceutical has received approval from the National Medical Products Administration for the injection of Nicorandil, which is classified as a Class 3 chemical drug for unstable angina, indicating a significant development in its product portfolio [1] Group 1: Product Approval - The injection of Nicorandil is approved with a specification of 12mg [1] - This drug was first launched in Japan in September 1993 and has not been imported as an original research product in China [1] Group 2: Market Potential - According to Mi Nei Network, the projected domestic market sales for Nicorandil in 2024 are approximately 620 million yuan [1] Group 3: R&D Investment - The company has invested around 6.78 million yuan in the research and development of this product [1] Group 4: Competitive Advantage - The approval of this product is seen as a means to enhance the company's product line and competitiveness, as it is considered to have passed the consistency evaluation [1] Group 5: Market Challenges - The production and sales of the drug may be influenced by various factors, indicating potential challenges in the market [1]

Financial Data and Key Metrics Changes - In Q3 2025, BRINSUPRI achieved $28 million in net sales, reflecting a strong early launch performance [32] - ARIKAYCE posted its largest quarter of revenue ever, up 22% year-over-year, with U.S. growth of 11% and international growth exceeding 50% [39][40] - The company raised its full-year global ARIKAYCE net revenue guidance to $420 million-$430 million, up from $405 million-$425 million previously [41] Business Line Data and Key Metrics Changes - BRINSUPRI's launch saw approximately 2,550 new patients starting treatment and about 1,700 physicians prescribing it within the first six weeks [32] - ARIKAYCE continues to perform strongly, with double-digit growth across all geographic regions [39] Market Data and Key Metrics Changes - The early days of BRINSUPRI's launch have shown broad prescribing patterns, with physicians testing the medicine on a small number of patients before wider adoption [33] - The U.S. market access for BRINSUPRI has been encouraging, with most prescriptions approved for coverage without formal contracts [36] Company Strategy and Development Direction - The company aims to position BRINSUPRI alongside leading respiratory launches like DUPIXENT and OFEV, targeting significant commercial opportunities [9] - Insmed is focused on executing multiple late-stage and commercial programs, including brensocatib and ARIKAYCE, while expanding its pipeline of earlier-stage programs [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the BRINSUPRI launch, emphasizing the need for more data from the first full quarter to assess long-term trends [51] - The company is well-capitalized with approximately $1.7 billion in cash, allowing it to support the launch of BRINSUPRI and other portfolio programs [41][43] Other Important Information - The company received a positive opinion from Europe's CHMP for brensocatib, anticipating a potential EU launch in early 2026 [12][13] - Insmed was awarded the number one ranking on Science Magazine's Top Employers list for the fifth consecutive year, highlighting its strong company culture [31] Q&A Session Summary Question: Early feedback on physician experience with BRINSUPRI - Management noted positive feedback from physicians, with enthusiasm for the medicine and manageable reimbursement processes during the early launch phase [47][49] Question: Thresholds for payer coverage and prior authorization - The company aims for clear and non-burdensome criteria for approval, focusing on patients with two or more exacerbations and confirmed diagnoses [54][56] Question: Dynamics of patient journey and DTC impact - There is clear enthusiasm from patients, with social media activity reflecting excitement about the new medicine [66] Question: Investment needed for European launch - The strategy involves cautious investment in Europe, ensuring reimbursement aligns before significant additional investments [70] Question: Phase III design considerations for TPIP - Management is confident in overcoming orphan drug exclusivity and plans to leverage insights from previous studies to inform the design of upcoming trials [75][78]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Beijing Wanhui Shuanghe Pharmaceutical Co., Ltd., has received a drug registration certificate for Alfacalcidol soft capsules from the National Medical Products Administration, which is expected to enhance the company's product line and market competitiveness [1][2]. Drug Registration Certificate Details - The drug is indicated for treating calcium metabolism disorders caused by insufficient endogenous 1,25-dihydroxyvitamin D3, including conditions such as renal osteodystrophy and osteoporosis [1][2]. - The company initiated the drug's generic research and development in August 2022, submitted the marketing authorization application in June 2024, and received approval on October 14, 2025 [2]. Market Situation - Alfacalcidol soft capsules were developed by LEO Pharma A/S and were approved for sale in the Netherlands in 1978 under the brand name "Etalpha," which was also approved in China in May 2023 [2]. - The global sales of Alfacalcidol capsules are projected to reach $182 million in 2024, with "Etalpha" contributing $14.13 million [2]. - In the Chinese market, there are nine approved manufacturers of Alfacalcidol soft capsules, with three having passed the consistency evaluation, including Wanhui Shuanghe [3]. - The total sales in the domestic medical and retail market for Alfacalcidol soft capsules are estimated at 659 million RMB in 2024, with the top three companies holding market shares of 36.53%, 17.65%, and 17.27% respectively [3].